Press "Enter" to skip to content

New patent for Biocryst drug RAPIVAB

1
Copyright © DrugPatentWatch. Originally published at New patent for Biocryst drug RAPIVAB

Annual Drug Patent Expirations for RAPIVAB
Annual Drug Patent Expirations for RAPIVAB

Rapivab is a drug marketed by Biocryst and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has sixty patent family members in twenty-eight countries.

The generic ingredient in RAPIVAB is peramivir. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Biocryst drug RAPIVAB

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions